Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Albertini

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Cancer Gene Therapy|March 17, 1999
Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogsG S Hogge, J K Burkholder, J Culp, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Modulation of target-cell culture conditions alters susceptibility to lymphocyte-mediated lysisM R Albertini, S P Howard, P Fisch, et al.
Cancer|December 18, 2001
Donor-derived small cell lung carcinoma in a kidney transplant recipientS Bodvarsson, W Burlingham, S Kusaka, et al.
Journal of Biological Response Modifiers|October 1, 1990
Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapyM R Albertini, K R Oettel, G Weil-Hillman, et al.
Cancer Gene Therapy|June 9, 2007
Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trialD M Mahvi, M B Henry, M R Albertini, et al.
Cancer|March 10, 2001
Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2M E Eastman, M Khorsand, D G Maki, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectorsJ E Surfus, J A Hank, E Oosterwijk, et al.
Human Gene Therapy|September 19, 1998
Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancerG S Hogge, J K Burkholder, J Culp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factorA L Rakhmilevich, M Imboden, Z Hao, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Analysis of T cell receptor beta and gamma genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patientsM R Albertini, J A Nicklas, B F Chastenay, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer Gene Therapy|March 17, 1999
Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogsG S Hogge, J K Burkholder, J Culp, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Modulation of target-cell culture conditions alters susceptibility to lymphocyte-mediated lysisM R Albertini, S P Howard, P Fisch, et al.
Cancer|December 18, 2001
Donor-derived small cell lung carcinoma in a kidney transplant recipientS Bodvarsson, W Burlingham, S Kusaka, et al.
Journal of Biological Response Modifiers|October 1, 1990
Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapyM R Albertini, K R Oettel, G Weil-Hillman, et al.
Cancer Gene Therapy|June 9, 2007
Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trialD M Mahvi, M B Henry, M R Albertini, et al.
Cancer|March 10, 2001
Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2M E Eastman, M Khorsand, D G Maki, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectorsJ E Surfus, J A Hank, E Oosterwijk, et al.
Human Gene Therapy|September 19, 1998
Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancerG S Hogge, J K Burkholder, J Culp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2001
Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factorA L Rakhmilevich, M Imboden, Z Hao, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Analysis of T cell receptor beta and gamma genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patientsM R Albertini, J A Nicklas, B F Chastenay, et al.
Pageof 3